Acura Pharmaceuticals is working on creating a next-generation pseudoephedrine formulation that will impede the extraction of pseudoephedrine from the tablets to form methamphetamine. Nexafed combines nasal-congestion relief with unique IMPEDE technology that disrupts the conversion of pseudoephedrine into methamphetamine. It utilizes an advanced polymer matrix to limit the extraction of pseudoephedrine from tablets.

The conversion of pseudoephedrine to methamphetamine has been a problem that has plagued the healthcare community for some time and has forced the decongestant to be removed from pharmacy shelves and placed behind pharmacy counters.  Acura anticipates that Nexafed will be accepted by the pharmacy community, especially locations that have been impacted the most by methamphetamine abuse.

Topline results from a clinical study demonstrated Nexafed is bioequivalent to the leading national brand product. The study was a Phase 1 pharmacokinetic study in 30 healthy adult subjects.

Nexafed will be available in 30mg dosage strength tablets in 24-count boxes. The launch is expected before the end of the year.

For more information call (847) 705-7709 or visit